Stanford University
The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.
The ketogenic diet is a low carbohydrate, moderate protein, higher fat diet to help individuals improve energy and mood and to obtain nutrients from fats and protein. Schizophrenia, bipolar disorder, and major depressive disorder, collectively affect about 344 million individuals worldwide, (24 million with schizophrenia, 40 million people with BD, and 280 million with depression World Health Organization). These illnesses are debilitating psychiatric conditions characterized by a chronic pattern of emotional, behavioral, and cognitive disturbances. Shared psychopathology includes the pre-emin…
Inclusion Criteria: 1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia 1. For individuals diagnosed with bipolar disorder (BD): * Meet DSM V criteria for BD (any subtype) * Not mild * \>40 on BPRS * clinically stable (with no hospitalization for past 3 months) 2. For individuals diagnosed with major depressive disorder (MDD): * Not mild * PHQ-9 \> 10 * clinically stable (with no hospitalization for past 3 months) 3. For individuals diagnosed with schizophrenia: * Meet DSM V criteria for sc…
Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks
Participant's usual diet
Arctuva estimate
Verify or correct the compensation shown for this listing.